LU-CHENG KUOCHONG-JEN YULI-NA LEEWang J.-L.HAO-CHIEN WANGPO-REN HSUEHPAN-CHYR YANG2020-12-022020-12-0220030929-6646https://www.scopus.com/inward/record.uri?eid=2-s2.0-0345865147&partnerID=40&md5=75be38fe438dc24d01720ee626051b79https://scholars.lib.ntu.edu.tw/handle/123456789/523908Background and Purpose: The number of infections caused by Acinetobacter baumanni has increased in recent years and the emergence of pandrug-resistant A. baumannii (PDRAB) has been observed in Taiwan. The aim of this study was to evaluate the clinical features and outcomes of patients with bacteremia due to PDRAB. Methods: From January 1999 to April 2003, 30 patients with PDRAB bacteremia were treated. We analyzed the clinical characteristics of these patients, including gender, underlying disease, clinical manifestations, antibiotic treatment, and outcome. Results: Bacteremia develope an average of 33 days after hospitalization and was hospital acquired in all cases. The source of bacteremia was identified in 19 patients (63.3%) and was most commonly from the respiratory tract. The overall mortality was 60% (18 patients). Among these, the cause of death was directly related to PDRAB bacteremia in 12. Underlying heart disease, shock, resuscitation, acute respiratory distress syndrome, mechinical ventilation, and multiple organ dysfunctin score (MODS) were significant predictors of mortality after the development of PDRAB bacteremia. No specific antimicrobial therapy appeared to be effective. Conclusion: Clinical outcomes of patients with PDRAB bacteremia were related to the medical conditions of the patients at the times of development of bacteremia and could be predicted by the MODS. The only way to limit the spread is through stricy preventive measures for nosocomial infection and antibiotic control.[SDGs]SDG3amikacin; aminoglycoside antibiotic agent; antibiotic agent; aztreonam; carbapenem derivative; cefepime; ceftazidime; cephalosporin; ciprofloxacin; gentamicin; imipenem; macrolide; meropenem; ofloxacin; penicillin G; piperacillin plus tazobactam; quinoline derived antiinfective agent; timentin; Acinetobacter baumannii; adult; aged; antibiotic resistance; antibiotic therapy; article; artificial ventilation; bacteremia; cause of death; clinical feature; controlled study; drug efficacy; female; gender; heart disease; hospital infection; hospitalization; human; infection control; infection prevention; major clinical study; male; mortality; multiple organ failure; outcomes research; prediction; respiratory distress; respiratory tract infection; resuscitation; scoring system; shock; Taiwan; university hospital; Acinetobacter baumannii; Acinetobacter Infections; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacteremia; Cross Infection; Drug Resistance, Multiple, Bacterial; Female; Hospitals, University; Humans; Male; Middle Aged; Taiwanjournal article146256032-s2.0-0345865147